OBJECTIVE: The objective of this study was to compare the safety and efficacy of inhaled plus intravenous (IV) colistin with that of IV colistin alone in critically ill children with ventilator-associated pneumonia (VAP) due to colistin-only susceptible (COS) Gram-negative bacteria (GNB). STUDY DESIGN AND PATIENTS: This retrospective cohort study included critically ill children aged 1 month to 18 years with culture-documented monomicrobial VAP due to COS GNB. RESULTS: Fifty patients were included, and 32 patients received IV colistin alone, whereas 18 patients received inhaled plus IV colistin. No between-cohort differences were observed in clinical (p = 0.49) and microbiological outcomes (p = 0.68), or VAP-related mortality (p = 0.99). Although the bacterial eradication rates did not differ in either treatment group, the median time to bacterial eradication (TBE) was significantly shorter in the inhaled plus IV colistin group than in the IV colistin group. The additional use of inhaled colistin was the only independent factor associated with TBE, and it shortened the median TBE by 3 days. Only one patient in the IV colistin group developed reversible nephrotoxicity. Mild bronchoconstriction was observed in three patients at the time of administration of the first doses of inhaled colistin, which did not require discontinuation of treatment. CONCLUSIONS: The present study has demonstrated that the addition of inhaled colistin to IV colistin led to a shorter TBE in critically ill children with VAP due to COS GNB. However, it did not lead to a significant difference in the clinical and microbiological outcomes of VAP.
OBJECTIVE: The objective of this study was to compare the safety and efficacy of inhaled plus intravenous (IV) colistin with that of IV colistin alone in critically ill children with ventilator-associated pneumonia (VAP) due to colistin-only susceptible (COS) Gram-negative bacteria (GNB). STUDY DESIGN AND PATIENTS: This retrospective cohort study included critically ill children aged 1 month to 18 years with culture-documented monomicrobial VAP due to COS GNB. RESULTS: Fifty patients were included, and 32 patients received IV colistin alone, whereas 18 patients received inhaled plus IV colistin. No between-cohort differences were observed in clinical (p = 0.49) and microbiological outcomes (p = 0.68), or VAP-related mortality (p = 0.99). Although the bacterial eradication rates did not differ in either treatment group, the median time to bacterial eradication (TBE) was significantly shorter in the inhaled plus IV colistin group than in the IV colistin group. The additional use of inhaled colistin was the only independent factor associated with TBE, and it shortened the median TBE by 3 days. Only one patient in the IV colistin group developed reversible nephrotoxicity. Mild bronchoconstriction was observed in three patients at the time of administration of the first doses of inhaled colistin, which did not require discontinuation of treatment. CONCLUSIONS: The present study has demonstrated that the addition of inhaled colistin to IV colistin led to a shorter TBE in critically ill children with VAP due to COS GNB. However, it did not lead to a significant difference in the clinical and microbiological outcomes of VAP.
Authors: I P Korbila; A Michalopoulos; P I Rafailidis; D Nikita; G Samonis; M E Falagas Journal: Clin Microbiol Infect Date: 2009-09-02 Impact factor: 8.067
Authors: Sofia K Kasiakou; Argyris Michalopoulos; Elpidoforos S Soteriades; George Samonis; George J Sermaides; Matthew E Falagas Journal: Antimicrob Agents Chemother Date: 2005-08 Impact factor: 5.191
Authors: Roberto Imberti; Maria Cusato; Paola Villani; Livio Carnevale; Giorgio A Iotti; Martin Langer; Mario Regazzi Journal: Chest Date: 2010-06-17 Impact factor: 9.410
Authors: Brian T Tsuji; Jason M Pogue; Alexandre P Zavascki; Mical Paul; George L Daikos; Alan Forrest; Daniele R Giacobbe; Claudio Viscoli; Helen Giamarellou; Ilias Karaiskos; Donald Kaye; Johan W Mouton; Vincent H Tam; Visanu Thamlikitkul; Richard G Wunderink; Jian Li; Roger L Nation; Keith S Kaye Journal: Pharmacotherapy Date: 2019-01 Impact factor: 6.251
Authors: Mohammad A K Azad; Jian Li; Maizbha U Ahmed; Mengyao Li; Darren J Creek; Meiling Han; Fanfan Zhou; Kim Chan; Qi Tony Zhou; Tony Velkov Journal: Antimicrob Agents Chemother Date: 2021-08-17 Impact factor: 5.191
Authors: Sami Abdellatif; Ahlem Trifi; Foued Daly; Khaoula Mahjoub; Rochdi Nasri; Salah Ben Lakhal Journal: Ann Intensive Care Date: 2016-03-31 Impact factor: 6.925